Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19
Hoertel N, Sanchez-Rico M, Kornhuber J, Gulbins E, Reiersen AM, Lenze EJ, Fritz BA, Jalali F, Mills EJ, Cougoule C, Carpinteiro A, Mühle C, Becker KA, Boulware DR, Blanco C, Alvarado JM, Strub-Wourgaft N, Lemogne C, Limosin F (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 11
Journal Issue: 19
DOI: 10.3390/jcm11195882
Abstract
To reduce Coronavirus Disease 2019 (COVID-19)-related mortality and morbidity, widely available oral COVID-19 treatments are urgently needed. Certain antidepressants, such as fluvoxamine or fluoxetine, may be beneficial against COVID-19. We included 388,945 adult inpatients who tested positive for SARS-CoV-2 at 36 AP-HP (Assistance Publique-Hopitaux de Paris) hospitals from 2 May 2020 to 2 November 2021. We compared the prevalence of antidepressant use at admission in a 1:1 ratio matched analytic sample with and without COVID-19 (N = 82,586), and assessed its association with 28-day all-cause mortality in a 1:1 ratio matched analytic sample of COVID-19 inpatients with and without antidepressant use at admission (N = 1482). Antidepressant use was significantly less prevalent in inpatients with COVID-19 than in a matched control group of inpatients without COVID-19 (1.9% versus 4.8%; Odds Ratio (OR) = 0.38; 95%CI = 0.35-0.41, p < 0.001). Antidepressant use was significantly associated with reduced 28-day mortality among COVID-19 inpatients (12.8% versus 21.2%; OR = 0.55; 95%CI = 0.41-0.72, p < 0.001), particularly at daily doses of at least 40 mg fluoxetine equivalents. Antidepressants with high FIASMA (Functional Inhibitors of Acid Sphingomyelinase) activity seem to drive both associations. These treatments may reduce SARS-CoV-2 infections and COVID-19-related mortality in inpatients, and may be appropriate for prophylaxis and/or COVID-19 therapy for outpatients or inpatients.
Authors with CRIS profile
Johannes Kornhuber
Lehrstuhl für Psychiatrie und Psychotherapie
Christiane Mühle
Department of Psychiatry and Psychotherapy
Involved external institutions
Université de Paris
France (FR)
Hôpital Corentin-Celton, Hospital Corentin-Celton, APHP
France (FR)
Universität Duisburg-Essen (UDE)
Germany (DE)
Washington University
United States (USA) (US)
McMaster University
Canada (CA)
Université Fédérale de Toulouse Midi-Pyrénées
France (FR)
University of Minnesota (UMN)
United States (USA) (US)
National Institute on Drug Abuse (NIDA)
United States (USA) (US)
Universidad Complutense de Madrid (UCM)
Spain (ES)
Drugs for Neglected Diseases initiative (DNDi)
Switzerland (CH)
France (FR)
Hôpital Corentin-Celton, Hospital Corentin-Celton, APHP
France (FR)
Universität Duisburg-Essen (UDE)
Germany (DE)
Washington University
United States (USA) (US)
McMaster University
Canada (CA)
Université Fédérale de Toulouse Midi-Pyrénées
France (FR)
University of Minnesota (UMN)
United States (USA) (US)
National Institute on Drug Abuse (NIDA)
United States (USA) (US)
Universidad Complutense de Madrid (UCM)
Spain (ES)
Drugs for Neglected Diseases initiative (DNDi)
Switzerland (CH)
How to cite
APA:
Hoertel, N., Sanchez-Rico, M., Kornhuber, J., Gulbins, E., Reiersen, A.M., Lenze, E.J.,... Limosin, F. (2022). Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19. Journal of Clinical Medicine, 11(19). https://doi.org/10.3390/jcm11195882
MLA:
Hoertel, Nicolas, et al. "Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19." Journal of Clinical Medicine 11.19 (2022).
BibTeX: Download